Stocks of Coherus Biosciences Inc (NASDAQ:CHRS) traded higher last session on Wall Street, up 14.02% to $3.01.
According to the data, Coherus Biosciences Inc (NASDAQ:CHRS) has 9 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. CHRS stock price is now -28.01% away from the 50-day moving average and -47.18% away from the 200-day moving average. The market capitalization of the company currently stands at $332.54M.
A total of 2 analysts have issued a hold rating and 6 have given it a buy rating.
With the price target of $12, Citigroup recently initiated with Buy rating for Coherus Biosciences Inc (NASDAQ: CHRS).
Insiders disposed of 56,868 shares of company stock worth roughly $0.17 million over the past 1 year. A total of 4.12% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in CHRS stock. A new stake in Coherus Biosciences Inc shares was purchased by POINT72 ASSET MANAGEMENT, L.P. during the first quarter worth $2,534,000. ARMISTICE CAPITAL, LLC invested $2,530,000 in shares of CHRS during the first quarter. In the first quarter, WOODLINE PARTNERS LP acquired a new stake in Coherus Biosciences Inc valued at approximately $1,320,000. KNOTT DAVID M JR acquired a new stake in CHRS for approximately $647,000. HRT FINANCIAL LP purchased a new stake in CHRS valued at around $617,000 in the second quarter. In total, there are 246 active investors with 79.75% ownership of the company’s stock.
Monday’s opening bell rang with an opening price of $3.0200 for Coherus Biosciences Inc (NASDAQ: CHRS). During the past 12 months, Coherus Biosciences Inc has had a low of $2.56 and a high of $10.99. The fifty day moving average price for CHRS is $4.1517 and a two-hundred day moving average price translates $5.6608 for the stock.
The latest earnings results from Coherus Biosciences Inc (NASDAQ: CHRS) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, beating analysts’ expectations of -$0.48 by 0.1. This compares to -$0.65 EPS in the same period last year. The net profit margin was -145.18% and return on equity was -1657.06% for CHRS. The company reported revenue of $58.72 million for the quarter, compared to $60.15 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -2.39 percent. For the current quarter, analysts expect CHRS to generate $83.56M in revenue.
Coherus Biosciences Inc(CHRS) Company Profile
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
